CY1114594T1 - Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη - Google Patents

Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη

Info

Publication number
CY1114594T1
CY1114594T1 CY20111100263T CY111100263T CY1114594T1 CY 1114594 T1 CY1114594 T1 CY 1114594T1 CY 20111100263 T CY20111100263 T CY 20111100263T CY 111100263 T CY111100263 T CY 111100263T CY 1114594 T1 CY1114594 T1 CY 1114594T1
Authority
CY
Cyprus
Prior art keywords
cyclosporin
etval
meala
pharmaceutical composition
composition including
Prior art date
Application number
CY20111100263T
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Grégoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm S.A. filed Critical Debiopharm S.A.
Publication of CY1114594T1 publication Critical patent/CY1114594T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση αυτή αφορά τη χρήση στη θεραπεία μόλυνσης από HCV, είτε ως μεμονωμένοι δραστικοί παράγοντες ή σε συνδυασμό με έναν άλλο δραστικό παράγοντα, μιας κυκλοσπορίνης που έχει αυξημένη συνδετική δραστικότητα προς κυκλοφιλίνη και ουσιαστικά στερείται ανοσοκατασταλτικής δραστικότητας.
CY20111100263T 2004-10-01 2011-03-08 Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη CY1114594T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
EP05791430A EP1793844B1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection

Publications (1)

Publication Number Publication Date
CY1114594T1 true CY1114594T1 (el) 2016-10-05

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100263T CY1114594T1 (el) 2004-10-01 2011-03-08 Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη

Country Status (30)

Country Link
US (3) US7439227B2 (el)
EP (1) EP1793844B1 (el)
JP (1) JP4892486B2 (el)
KR (1) KR101191833B1 (el)
CN (1) CN101056648B (el)
AT (1) ATE490778T1 (el)
AU (1) AU2005290984B2 (el)
BR (1) BRPI0515494A (el)
CA (1) CA2580448C (el)
CY (1) CY1114594T1 (el)
DE (1) DE602005025232D1 (el)
DK (1) DK1793844T3 (el)
EA (1) EA012650B1 (el)
ES (1) ES2357587T3 (el)
GE (1) GEP20104960B (el)
HK (1) HK1104236A1 (el)
HR (1) HRP20110169T1 (el)
IL (1) IL182362A0 (el)
MA (1) MA28950B1 (el)
MX (1) MX2007003387A (el)
NZ (1) NZ554412A (el)
PL (1) PL1793844T3 (el)
PT (1) PT1793844E (el)
RS (1) RS51614B (el)
SG (1) SG139750A1 (el)
SI (1) SI1793844T1 (el)
TN (1) TNSN07084A1 (el)
UA (1) UA88484C2 (el)
WO (1) WO2006038088A1 (el)
ZA (1) ZA200702610B (el)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
CN1984671A (zh) 2004-07-14 2007-06-20 诺瓦提斯公司 环孢菌素和peg化干扰素的组合用于治疗丙型肝炎病毒(hcv)的用途
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7696167B2 (en) 2004-11-22 2010-04-13 Astellas Pharma Inc. Cyclic peptide compound
US20090214464A1 (en) * 2004-12-23 2009-08-27 Beat Weidmann Compounds for flaviviridae treatment
RU2007128099A (ru) * 2004-12-23 2009-01-27 Новартис АГ (CH) Композиции для лечения гепатита с
BRPI0613142A2 (pt) * 2005-06-17 2010-12-21 Novartis Ag uso de sangliferina em hcv
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
WO2007041632A2 (en) 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
BRPI0617781A2 (pt) 2005-10-26 2011-08-09 Astellas Pharma Inc compostos de peptìdeos cìclicos
JP5167244B2 (ja) 2006-04-11 2013-03-21 ノバルティス アーゲー Ｈｃｖ／ｈｉｖ阻害剤およびそれらの使用
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
MX2009003743A (es) * 2006-10-12 2009-06-18 Novartis Ag Uso de ciclosporinas modificadas.
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
MX2009011512A (es) 2007-05-02 2009-11-12 Astellas Pharma Inc Nuevos compuestos peptidos ciclicos.
WO2009042892A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
CA2724523A1 (en) 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
KR20110093858A (ko) * 2008-11-06 2011-08-18 데비오 레쉑쉐 빠르마슈띠끄 에스.아 시클로운데카뎁시펩티드 화합물 및 약제로서 상기 화합물의 용도
AU2009334790B2 (en) 2008-12-31 2016-09-08 Scynexis, Inc. Derivatives of cyclosporin A
NZ594755A (en) 2009-01-30 2013-12-20 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US20130225483A1 (en) * 2010-10-05 2013-08-29 Claudio Avila New Treatments of Hepatitis C Virus Infection
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
RU2013129824A (ru) * 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
BR112013025021A2 (pt) 2011-03-31 2017-03-01 Novartis Ag alisporivir para tratar infecções por vírus de hepatite c.
ES2533213T3 (es) * 2011-04-01 2015-04-08 Novartis Ag Tratamiento para infección con el virus de hepatitis B solo o en combinación con el virus de hepatitis Delta y enfermedades hepáticas asociadas
MA35029B1 (fr) 2011-04-13 2014-04-03 Novartis Ag Traitement de l'infection par le virus de l'hépatite c avec l'alisporivir
KR20140070565A (ko) * 2011-09-27 2014-06-10 노파르티스 아게 C형 간염 바이러스 감염의 치료를 위한 알리스포리비르
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
MX2014013625A (es) 2012-05-07 2015-02-05 Novartis Ag Modulacion farmacocinetica con alisporivir.
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
CN105579046A (zh) 2013-08-26 2016-05-11 英安塔制药有限公司 用于预防或治疗丙型肝炎的环孢菌素类似物
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI780152B (zh) 2017-05-12 2022-10-11 日商中外製藥股份有限公司 環狀有機化合物的製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU759480B2 (en) * 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20070073761A (ko) 2007-07-10
JP2008514690A (ja) 2008-05-08
SI1793844T1 (sl) 2011-05-31
HK1104236A1 (en) 2008-01-11
UA88484C2 (ru) 2009-10-26
IL182362A0 (en) 2007-07-24
CA2580448C (en) 2012-09-18
DE602005025232D1 (de) 2011-01-20
CA2580448A1 (en) 2006-04-13
GEP20104960B (en) 2010-04-26
EP1793844A1 (en) 2007-06-13
EA200700725A1 (ru) 2007-10-26
BRPI0515494A (pt) 2008-07-29
ES2357587T3 (es) 2011-04-27
AU2005290984A1 (en) 2006-04-13
CN101056648A (zh) 2007-10-17
ZA200702610B (en) 2008-08-27
ATE490778T1 (de) 2010-12-15
CN101056648B (zh) 2012-08-15
NZ554412A (en) 2011-01-28
HRP20110169T1 (hr) 2011-04-30
MX2007003387A (es) 2007-05-23
US20060252675A1 (en) 2006-11-09
EP1793844B1 (en) 2010-12-08
TNSN07084A1 (en) 2008-06-02
PT1793844E (pt) 2011-03-10
WO2006038088A1 (en) 2006-04-13
US7772184B2 (en) 2010-08-10
USRE43371E1 (en) 2012-05-08
US20090081164A1 (en) 2009-03-26
SG139750A1 (en) 2008-02-29
RS51614B (en) 2011-08-31
AU2005290984B2 (en) 2010-09-09
PL1793844T3 (pl) 2011-05-31
KR101191833B1 (ko) 2012-10-16
MA28950B1 (fr) 2007-10-01
US7439227B2 (en) 2008-10-21
JP4892486B2 (ja) 2012-03-07
EA012650B1 (ru) 2009-12-30
DK1793844T3 (da) 2011-03-21

Similar Documents

Publication Publication Date Title
CY1114594T1 (el) Χρηση της [d-meala]3[etval]4-κυκλοσπορινης για την θεραπεια μολυνσης απο ηπατιτιδα c και φαρμακευτικη συνθεση που περιλαμβανει την εν λογω [d-meala]3[etval]4-κυκλοσπορινη
WO2005102392A3 (en) Combinations for treating hiv infection
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
ATE276764T1 (de) Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
BR0113666A (pt) Inibidores da protease peptidomimética
WO2006034001A3 (en) Methods of treating hiv infection
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
MA26317A1 (fr) Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.
HUP0105070A2 (hu) Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
EP1185283A4 (en) NEW THERAPEUTIC USE OF A VIRAL INJECTION MODULATING PROTEIN TO PREVENT EXHAUST FROM FOREIGN TRANSPLANTS
WO2004033479A3 (en) Retroyclins: antiviral and antimicrobial peptides
SE0000303D0 (sv) Novel compounds
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
JP2006527741A5 (el)
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE
WO2002002087A3 (de) Anthelmintika zur verhinderung von parasitären infektionen bei menschen und tieren ii
RU2001100069A (ru) Антгельминтное средство
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
UA93036C2 (ru) Лактамные соединения и применение в качестве фармацевтических препаратов
HUP0300083A2 (hu) Készítmény immunszupresszív szerek alkalmazása által indukált citotoxikus hatások kezelésére és/vagy megelőzésére